JPWO2021155180A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155180A5 JPWO2021155180A5 JP2022544181A JP2022544181A JPWO2021155180A5 JP WO2021155180 A5 JPWO2021155180 A5 JP WO2021155180A5 JP 2022544181 A JP2022544181 A JP 2022544181A JP 2022544181 A JP2022544181 A JP 2022544181A JP WO2021155180 A5 JPWO2021155180 A5 JP WO2021155180A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination according
- seq
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 229940121647 egfr inhibitor Drugs 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960003278 osimertinib Drugs 0.000 claims 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical group COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101150039808 Egfr gene Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000016978 Orphan receptors Human genes 0.000 claims 1
- 108070000031 Orphan receptors Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- UOFYSRZSLXWIQB-UHFFFAOYSA-N abivertinib Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 UOFYSRZSLXWIQB-UHFFFAOYSA-N 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 108700021358 erbB-1 Genes Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229940121300 mavelertinib Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- JYIUNVOCEFIUIU-GHMZBOCLSA-N n-[(3r,4r)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide Chemical compound COC1=NN(C)C=C1NC1=NC(N2C[C@H]([C@H](F)C2)NC(=O)C=C)=NC2=C1N=CN2C JYIUNVOCEFIUIU-GHMZBOCLSA-N 0.000 claims 1
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 229950000908 nazartinib Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- -1 olumtinib Chemical compound 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229950009855 rociletinib Drugs 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968121P | 2020-01-30 | 2020-01-30 | |
| US62/968,121 | 2020-01-30 | ||
| US202063011036P | 2020-04-16 | 2020-04-16 | |
| US63/011,036 | 2020-04-16 | ||
| PCT/US2021/015749 WO2021155180A1 (en) | 2020-01-30 | 2021-01-29 | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512181A JP2023512181A (ja) | 2023-03-24 |
| JPWO2021155180A5 true JPWO2021155180A5 (zh) | 2024-02-02 |
Family
ID=77079208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544181A Pending JP2023512181A (ja) | 2020-01-30 | 2021-01-29 | 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230070988A1 (zh) |
| EP (1) | EP4097137A4 (zh) |
| JP (1) | JP2023512181A (zh) |
| KR (1) | KR20220140534A (zh) |
| CN (1) | CN115485298A (zh) |
| AU (1) | AU2021214581A1 (zh) |
| CA (1) | CA3169455A1 (zh) |
| TW (1) | TW202140016A (zh) |
| WO (1) | WO2021155180A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024123126A1 (ko) * | 2022-12-09 | 2024-06-13 | 재단법인대구경북과학기술원 | 올무티닙을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6911019B2 (ja) * | 2016-05-17 | 2021-07-28 | 公益財団法人がん研究会 | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 |
| WO2018237335A1 (en) * | 2017-06-23 | 2018-12-27 | VelosBio Inc. | IMMUNOCONJUGUATED ROR1 ANTIBODIES |
| CN110869389B (zh) * | 2017-06-25 | 2023-07-28 | 西雅图免疫公司 | 抗ror1抗体及其制备和使用方法 |
-
2021
- 2021-01-29 KR KR1020227029753A patent/KR20220140534A/ko unknown
- 2021-01-29 CA CA3169455A patent/CA3169455A1/en active Pending
- 2021-01-29 TW TW110103582A patent/TW202140016A/zh unknown
- 2021-01-29 AU AU2021214581A patent/AU2021214581A1/en active Pending
- 2021-01-29 JP JP2022544181A patent/JP2023512181A/ja active Pending
- 2021-01-29 US US17/759,681 patent/US20230070988A1/en active Pending
- 2021-01-29 WO PCT/US2021/015749 patent/WO2021155180A1/en unknown
- 2021-01-29 EP EP21748091.2A patent/EP4097137A4/en active Pending
- 2021-01-29 CN CN202180025836.5A patent/CN115485298A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2346702C2 (ru) | Применение антител к ctla-4 | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2021102627A5 (zh) | ||
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| JP2020103301A5 (zh) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2008532488A5 (zh) | ||
| JP2024029049A5 (zh) | ||
| HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
| JP2008529494A5 (zh) | ||
| RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
| JP2009539403A5 (zh) | ||
| RU2006137060A (ru) | Человеческие антитела к рецептору эпидермального фактора роста | |
| RU2008142833A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met | |
| US20170122950A1 (en) | ANTIBODIES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES | |
| JP2008508858A5 (zh) | ||
| JP2008531576A5 (zh) | ||
| JP2008526256A5 (zh) | ||
| IL262856A (en) | Treatment of neoplastic diseases | |
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JPWO2019005636A5 (zh) | ||
| JPWO2021155180A5 (zh) | ||
| JPWO2019160751A5 (zh) |